{"slug":"other","open_questions":[{"id":"open_question-c5f4f361-bccc-45f0-9fd0-1d6c00252f16","title":"Mechanistic understanding**: How does alpha-synuclein spread through autonomic networks?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-9d844f47-a090-4576-ad91-8be549959d63","title":"How does the spreading pattern correlate with clinical progression?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-6ce14522-f4f2-48cf-a458-360ed896a924","title":"How do environmental toxins interact with mitochondrial pathways?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-c939f411-d7b5-46c7-af85-42be1201e71d","title":"Which combination of biomarkers provides optimal prodromal detection?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-brain-regions-amygdala-e6565094","title":"Single-nucleus sequencing","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-brain-regions-amygdala-c3aa8499","title":"Light-sheet microscopy","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-brain-regions-amygdala-edeac57f","title":"AI-assisted diagnosis","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-brain-regions-amygdala-6737ef5a","title":"Personalized medicine","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-5d76508a-65b5-4f78-bb99-ed606db1615c","title":"What triggers the initial misfolding of alpha-synuclein in sporadic PD?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-b09ea146-2bdc-48a0-a619-b7a36b9d045c","title":"Can targeting propagation halt disease progression in established PD?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-13cc4c56-4e84-4e1b-856b-175f66f530ae","title":"What is the normal physiological function of LRRK2, and how do pathogenic mutations disrupt it?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-14d10ec2-ac36-41f3-8550-6a0239bdc873","title":"How do GBA mutations modify alpha-synuclein pathology and treatment response?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-0c2deb0d-4057-4421-818e-f0892d5ff199","title":"Can gene-specific therapies be developed for different genetic subtypes?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-c3ce6b15-edee-4627-b2d3-cfd75a9a692d","title":"What is the relative contribution of mitochondrial dysfunction to dopaminergic neuron loss?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-ac0f3f39-cc4e-4d7c-ad45-5cdb4525b8d1","title":"Can pharmacological activation of mitophagy compensate for PINK1/PARKIN deficiency?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-f5356424-1b4c-4fa2-91e0-207d2b3eb418","title":"What is the timeline from prodromal to clinical PD diagnosis?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-90cfbb93-85c2-49c2-ac79-cf2517638833","title":"Can prodromal intervention prevent progression to overt PD?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-ddeebe1a-d450-4a57-baad-e1d29d27ad47","title":"What determines whether a patient develops tau versus TDP-43 pathology?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-c2de4b0f-e65f-4772-9f03-0f3b6c23c9dc","title":"How do the different subtypes (bvFTD, svPPA, nfPPA) relate to specific proteinopathies?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-217fd038-ebbf-495a-96ec-9358c36f9bdc","title":"Mechanistic understanding**: How does amyloid disrupt DMN function?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5}],"open_questions_total":20,"knowledge_gaps":[{"id":"gap-pubmed-20260410-170109-8aff6b9b","title":"What determines the specificity and efficiency of mitochondrial uptake by different brain cell types in vivo?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-174005-2f2fc1ab","title":"Why do therapeutic effects persist for 6 months after single ds-cRNA administration?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-181230-4cdd6f61","title":"What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain barrier via intranasal delivery?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-181928-6e8d528b","title":"What are the specific translational challenges preventing IR agonist therapies from reaching clinical practice?","domain":"immunotherapy","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-181928-f28f0326","title":"How do agonistic IR antibodies achieve selective immune suppression without compromising protective immunity?","domain":"immunotherapy","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-182535-34deab1f","title":"What mechanisms underlie IL18's enhancement of CAR T cell cytolytic function against solid tumors?","domain":"cancer immunotherapy","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-182535-48b3c443","title":"How does antigen-inducible cytokine production compare to constitutive expression for CAR T cell persistence?","domain":"cancer immunotherapy","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260411-072417-76e9c437","title":"How can gene therapy expression be precisely controlled on-demand for the delicate excitatory/inhibitory balance in epilepsy?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260411-072417-b40dfc53","title":"How can cell-autonomous gene therapy treatments be designed to address epilepsy's complex pathogenic mechanisms?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0}],"gap_count":9,"landscape":null,"hypothesis_count":0,"personas":[{"id":"theorist","name":"Theorist","type":"debater","icon":"🧠","color":"#4fc3f7","debate_count":444},{"id":"skeptic","name":"Skeptic","type":"debater","icon":"⚠️","color":"#ffd54f","debate_count":443},{"id":"domain_expert","name":"Domain Expert","type":"debater","icon":"💊","color":"#81c784","debate_count":427},{"id":"synthesizer","name":"Synthesizer","type":"analyst","icon":"📊","color":"#ce93d8","debate_count":387},{"id":"clinical_trialist","name":"Clinical Trialist","type":"reviewer","icon":"📋","color":"#4dd0e1","debate_count":20},{"id":"computational_biologist","name":"Computational Biologist","type":"analyst","icon":"🧬","color":"#7986cb","debate_count":18},{"id":"ethicist","name":"Ethicist","type":"reviewer","icon":"⚖️","color":"#f48fb1","debate_count":8},{"id":"hongkui-zeng","name":"Hongkui Zeng","type":"debater","icon":"🧬","color":"#66bb6a","debate_count":7},{"id":"medicinal_chemist","name":"Medicinal Chemist","type":"builder","icon":"🧪","color":"#aed581","debate_count":7}]}